The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The Europe Airway Clearance System Market would witness market growth of 4.22% CAGR during the forecast period (2019-2025).
In Europe, the cost structure of home care and hospitals or psychiatric facilities differs widely due to the quality of services provided by respiratory care providers or suppliers, which include certain types of surveillance and hospitality services. Nevertheless, in the case of HCFWO, the cost could get as high as US$ 20,000. Compared to in-lab study, home airway clearance systems are cheaper.
The airway clearance systems market is very competitive and has the involvement of Tier 1 and Tier 2 companies as well as many small businesses. Over the projected period, these companies will engage in several distribution alliances to gain a substantial market share. Throughout the years, existing market players have developed a brand image and value which has made market penetration highly complex for new players.
The growing adoption of airway clearance systems for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and chronic bronchitis drives market growth. COPD is the third leading cause of death worldwide, according to the World Health Organization (WHO) 2019 report. Cystic fibrosis (CF) is a lifesaving genetic disease that affects multiple organs, particularly the lungs. Heterozygote prevalence in white people is assessed as being as high as one in every 20. There was a sharp increase in the number of CF patients in the UK alone from 10,338 (2012) to 10,509 (2018), as reported by the Cystic Fibrosis Trust in 2019. This is anticipated to accelerate the adoption of airway clearance systems over the forecast period.
Based on Type, the market is segmented into Positive Expiratory Pressure (PEP), Mechanical Cough Assist, High Frequency Chest Wall Oscillation (HFCWO), Oscillating PEP devices and Intrapulmonary Percussive Ventilators. Based on Application, the market is segmented into Cystic Fibrosis, Neuromuscular, Bronchiectasis, Emphysema and Other Applications. Based on End Use, the market is segmented into Home Care Settings, Ambulatory Surgical Centers, Hospitals & Clinics and Other End Use. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Allergan PLC, Electromed, Inc., Hill-Rom Holdings, Inc., General Physiotherapy, Inc., Thayer Medical Corporation, Vortran Medical Technology, Inc, Monaghan Medical Corporation, PARI GmbH (PARI Medical Holdings), and International Biophysics Corporation.
Scope of the Study
- Positive Expiratory Pressure (PEP)
- Mechanical Cough Assist
- High Frequency Chest Wall Oscillation (HFCWO)
- Oscillating PEP devices and
- Intrapulmonary Percussive Ventilators
- Cystic Fibrosis
- Emphysema and
- Other Applications
By End Use
- Home Care Settings
- Ambulatory Surgical Centers
- Hospitals & Clinics and
- Other End Use
- Rest of Europe
- Koninklijke Philips N.V.
- Allergan PLC
- Electromed, Inc.
- Hill-Rom Holdings, Inc.
- General Physiotherapy, Inc.
- Thayer Medical Corporation
- Vortran Medical Technology, Inc
- Monaghan Medical Corporation
- PARI GmbH (PARI Medical Holdings)
- International Biophysics Corporation
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free